fraction (PAF) to estimate the economic burden associated with the various RFs. PAF is a statistic that combines two facets of a RF and its impact on disease: relative risk (RR) of the RF in reference to a particular disease, and the prevalence of exposure to the RF in the population of interest.
Relative risk
The sources for the RRs associated with excess weight and physical inactivity remain the same as in the previously published model. 9, 17 The 2013 study on 1.3 million UK women was used as the source for RR data associated with tobacco smoking. 2 RRs were adjusted for geographic region, age, body mass index (BMI), socio-economic status, current alcohol intake, weekly strenuous physical activity, height, oral contraceptive use, menopausal status and menopausal hormone therapy use. RRs are also presented by three levels of smoking intensity based on the number of cigarettes smoked per day at the time of study recruitment, namely <10, 10-19 or ≥20.
The relative risk data for excess weight is specific to males and females while the source of RR data for physical inactivity did not make this distinction. An additional review of research for sex variations associated with physical inactivity and the risk of stroke, 18 colon 19 and rectal cancers, 20 supported the assumption that there is no significant difference in RR between males and females for this RF. The source of RR data for tobacco smoking is based on females only. Recent information suggests a convergence in RR between females and males, especially when adjusted for smoking intensity. 5 Even without adjusting for smoking intensity, Jha and colleagues found no significant differences between the sexes in adjusted hazard ratios for various causes of death in current smokers, including cancers, vascular diseases, respiratory diseases and all causes. 1 We therefore assumed that the RRs by smoking intensity would be the same for males and females by disease category.
The point estimates of the RRs are used for calculations in the base model with the upper and lower bounds of the 95% confidence intervals assessed in a sensitivity analysis.
Risk factor exposure
The other half of a PAF calculation depends on high-quality RF prevalence data. 21 The analysis of Canada's population exposure to tobacco smoking, physical inactivity and overweight/obesity began with information drawn from the 2010 Canadian Community Health Survey (CCHS). First, overweight and obese individuals were those with a BMI of between 25 kg/m 2 and 30 kg/m 2 for overweight and 30 kg/m 2 or greater for obesity, calculated based on selfreported height and weight. For youth aged 12 to 17, the Cole system of BMI was used to determine overweight and obesity rates. 22 Second, tobacco smokers were grouped into light (<10 cigarettes per day), moderate (10-19 per day) and heavy (≥20 per day) smokers based on additional details on the average Reduction in risk of mortality after smoking cessation, relative to current smokers, females by cause and by year since smoking cessation Coronary Heart Disease number of cigarettes smoked per day. 23 All current smokers who identified themselves as occasional smokers were included in the "light" smoking category. Third, physically inactive individuals were those categorized in the CCHS as "inactive."
We made one adjustment to these base CCHS data, namely estimating the rates of overweight, obesity and physical inactivity for children aged less than 12 years based on the sex-specific rates for 12-14 year olds in the CCHS. We assumed no smoking occurs in children younger than 12 years of age.
Multiple exposure levels
The most basic version of a PAF calculation, derived from the prevalence of a single RF and the RR of a related disease, uses the formula (E(RR−1)) / (E(RR−1)+ 1)), where E is the proportion of the population exposed to the factor of interest and RR is the relative risk of disease developing in the group exposed to the factor.
More sophisticated approaches are required to calculate PAF when a polytomous RF is involved. 24 This is the case for both the excess weight and the tobacco smoking RFs in the current model. Overweight and obesity should be conceived as a trichotomous exposure to excess body weight; i.e., 1) no excess weight, 2) intermediate excess or overweight (prevalence E OW ), and 3) more extreme excess or obesity (prevalence E OB ). The PAF calculation is as follows:
(E OW (RR OW −1) + E OB (RR OB −1)) / (E OW (RR OW −1) + E OB (RR OB −1) + 1)) Tobacco smoking, on the other hand, should be conceived as a tetrachotomous exposure; i.e., 1) non-smoker, 2) light smoker (prevalence E TSL ), 3) moderate smoker (prevalence E TSM ), and 4) heavy smoker (prevalence E TSH ). The PAF calculation is as follows:
(E TSL (RR TSL −1) + E TSM (RR TSM −1) + E TSH (RR TSH −1)) / (E TSL (RR TSL −1) + E TSM (RR TSM −1) + E TSH (RR TSH −1) + 1))
Calculating and adjusting costs
We estimated the economic burden using a prevalence-based cost-of-illness approach, and reported this in 2012 Canadian dollars. We began calculating direct costs using the approach adopted by Anis et al. 11 In short, direct costs, including hospital care, physician services, other health care professionals (but excluding dental services), drugs, health research and "other" health care expenditures were extracted from the National Health Expenditure Database for Canada. 25 All costs (except hospital care) were allocated to each of the co-morbidity categories based on weights published in the Economic Burden of Illness in Canada (EBIC) for 1998. 26 Hospital costs were allocated to each co-morbidity based on the proportion of total patient bed-days (based on data from the Canadian Institute for Health Information (CIHI) Hospital Morbidity Database 2000/2001 27 ) used in treating patients in Canada with that co-morbidity. Estimated total direct costs were distributed between males and females based on the proportion of hospital bed-days in 2000/2001 utilized by males and females for each of the co-morbidities. Finally, the Canadian sex-specific costs by co-morbidity were multiplied by the calculated sex-and comorbidity-specific PAF. We calculated indirect costs (premature mortality, short-and long-term disability) following the method used in EBIC, 1998 (a modified human-capital approach).
Economic benefits of risk factor reduction
A number of key assumptions were made in modelling the economic benefits associated with future RF reduction in the Canadian population. First, population projections for the 20-year timeframe from 2012 to 2031 by sex and five-year age group were based on projections by Statistics Canada. 28 Second, RF prevalence by sex and five-year age group was calculated for 2010 using the CCHS 2010 Public Use Microdata File. 23 Third, the base model uses a constant 1% relative annual reduction in the RFs of tobacco smoking, physical inactivity and excess weight. Current trends of decreasing smoking prevalence and increasing weight and inactivity are not factored into the model. Fourth, constant 2012 dollars are used throughout the modelling process (i.e., no adjustments are made for projected inflation) in order to clearly identify changes in the economic burden associated with changing RF prevalence, rather than confusing these results with inflationary increases. Fifth, obese individuals move into the overweight category while overweight individuals move into the healthy weight category. Sixth, the benefits associated with physical activity and moving to a healthier weight accrue within a year. 29 Last, the benefits of smoking cessation accrue over time, as per Figure 1 . Table 1 shows the fully adjusted prevalence of RF exposure, the statistically significant RR data by sex and the calculated PAF of disease incidence related to each RF. The PAF for all co-morbidities, with the obvious exception of gynecological and breast cancers, vary by sex. This type of detailed analysis has important implications in determining direct and indirect costs. Total Cost ($000,000)
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RESULTS
these RFs is $50.3 billion ($15.4/$34.9 billion in direct/indirect costs). Figure 2 represents the RF-specific burden graphically, with additional information on the components that constitute the indirect costs. The indirect burden related to premature mortality dominates as an outcome of tobacco smoking ($9.7 billion, or 68% of $14.3 billion in total indirect costs for that RF) and is also marginally higher than disability in the case of physical inactivity. The reverse is true for excess weight, where the economic burden of disability ($8.1 billion) outstrips the costs of premature mortality ($5.5 billion).
This analysis indicates that the disaggregated economic burden for excess weight in Canada in 2012 at $19.0 billion remains lower than the economic burden related to tobacco smoking at $21.3 billion.
It appears that cardiovascular diseases tend to dominate the disease burden that is attributable to these RFs. Of the $50.3 billion in annual economic burden, $21.0 billion (41.8%) is associated with cardiovascular diseases, $9.8 billion (19.4%) with cancers, $9.3 billion (18.5%) with musculoskeletal diseases, $6.6 billion (13.2%) with respiratory diseases and $3.2 billion (6.4%) with diabetes (see Figure 3) . Table 3 provides a summary of the estimated number of individuals in Canada with the RFs in 2012 and compares them to 2031 with either an assumption of no change or a 1% relative annual reduction in RF prevalence. With a 1% reduction, the proportion of Canadians who smoke would decrease from 17.9% in 2012 to 13.6% in 2031. In terms of absolute numbers of Canadians who smoke, the decrease would be from 6.2 million in 2012 to 5.7 million in 2031. The proportion of Canadians with excess weight would decrease from 42.9% to 38.7% while the proportion of physically inactive Canadians would decrease from 44.3% to 37.5%.
The economic burden associated with these RFs in Canada would increase from $50.3 billion in 2012 to $59.2 billion in 2031 (in constant 2012 dollars), assuming no change in RF prevalence, i.e., based solely on population growth (see Table 4 ). A 1% relative annual reduction in each of the three RFs would result in this projected economic burden of $59.2 billion decreasing to $50.8 billion (-$8.5 billion) in 2031. This reduction consists of $3.2, $3.1 and $2.1 billion, respectively, for decreases in excess weight, tobacco smoking and physical inactivity (see Figure 4) . Over the 20-year period from 2012 to 2031, a 1% relative annual reduction in these RFs would result in an estimated cumulative reduction in economic burden of $78.0 billion (consisting of $31.2, $26.4 and $20.3 billion, respectively, for decreases in excess weight, tobacco smoking and physical inactivity).
Sensitivity analysis
The point estimates for RR are used in the base model results presented above. We used the lower and upper bounds of the 95% CI for the RR associated with each RF and disease in a sensitivity analysis. Using the lower bounds resulted in a decrease in the total estimated economic burden in 2012 from $50.3 billion to $41.6 billion (or -17.3%) while applying the upper bounds increased the total economic burden to $58.7 billion in 2012 (or +16.7%) (see Table 5 ).
DISCUSSION
The annual economic burden of the RFs of tobacco smoking, excess weight and physical inactivity in Canada are estimated at 25 The total direct health care costs attributable to tobacco smoking, excess weight and physical inactivity of $15.4 billion represents 7.4% of this total. Kaiserman estimated smoking attributable health care costs in Canada in 1991 to be $2.5 billion, 12 or about 3.8% of the $66.3 billion total health care costs in Canada that year. 25 Similarly, Rehm and colleagues estimated smoking attributable health care costs in Canada in 2002 to be $4.4 billion, 31 or 3.8% of the $115.1 billion total health care costs in Canada that year. 25 Our finding of 3.4% ($7.0 of $207.4 billion) may be at least partially attributable to a reduction in smoking prevalence from 25.9% to 19.9% of the population aged 12 and over in Canada during the last decade 32 as well as adjustments made to avoid double counting. Katzmarzyck and Janssen estimated the direct health care costs attributable to physical inactivity and obesity to be $1.6 billion each in 2001, 9 or 1.5% of the $107.2 billion total health care costs in Canada that year. 25 Our estimate of 2.6% for excess weight includes both overweight and obesity. Including just obesity would reduce direct care costs to 1.7% ($3.5 of $207.4 billion), or slightly higher than the 1.5% estimated by Katzmarzyck and Janssen. Anis and colleagues estimated the combined direct costs of overweight and obesity in Canada in 2006 to be $6.0 billion, or 4.0% of the $150.8 billion total health care costs in Canada that year. 25 Of the $6.0 billion, approximately $4.0 billion (or 2.6% of $150.8 billion) is attributable to obesity. Our estimate of 1.4% ($3.0 billion of $207.4 billion) attributable to physical inactivity is somewhat lower than previous estimates of 1.5%. 9 Lower estimates of the direct costs attributable to tobacco smoking, excess weight and physical inactivity observed in the current study compared with previous Canadian studies may be at least partially due to addressing double counting when assessing the economic impact of multiple RFs within the population. In addressing double counting, the aggregate economic burden was 13.4% lower than the total that would be generated by crude summation of costs generated by each of the three RFs.
Another important result, generated by having access to sexspecific RF prevalence and RR data, is the difference between males and females in contributing to the total economic burden. Of the $50.3 billion, $26.5 billion (52.8%) is attributable to males and $23.8 billion to females. The costs associated with tobacco smoking, however, are higher for males ($13.0 billion) than for females ($8. among women) and the fact that a higher proportion of men are heavy smokers (6.5% vs. 3.0%). The overall sex-specific distribution for the burden of key modifiable RFs has important implications for prevention planning and public health messaging. Our analysis suggests that even a modest 1% annual relative reduction in the RFs of tobacco smoking, excess weight and physical inactivity can have a substantial health and economic impact over time at the population level. Indeed, such a change could bend the cost curve over a 20-year period to the point where the economic burden associated with these RFs would remain essentially constant despite the projected growth in Canada's population from 33 million in 2012 to 42 million in 2031.
The analysis of the economic burden related to the RF system and the individual RFs is the first phase of any attempt to project the potential economic impact of applying known primary prevention initiatives. A key question is whether a 1% annual relative reduction in these RFs, as assumed in the current analysis, is achievable over the long term. Between 2001 and 2011, smoking rates in Canada fell from 25.9% to 19.9% for the population aged 12 and over 32 (a 2.6% relative annual reduction). There are also a number of promising approaches worldwide which include addressing the RFs of excess weight and physical inactivity, 33 such as the experience in North Karelia, Finland. 34, 35 The quality of the results derived from a PAF analysis is inevitably limited by the quality of the inputs, specifically RR and prevalence data. A potential weakness in this study is the lack of RR information based on Canadian data. A sensitivity analysis using the 95% CI associated with each RR indicates the importance of using robust and accurate RR estimates. The economic modelling also uses older data from CIHI and the EBIC for cost allocation purposes, requiring the assumption that the distribution of costs have not changed significantly for specific cost categories over time. Similarly, the method of scaling up from direct costs to indirect costs depends on the assumption that the ratios of costs between different co-morbidities are the same for direct and indirect costs. Changes in economic burden of smoking, excess weight and physical inactivity, 1% reduction in risk factor prevalence compared to no reduction, Canada, 2012- 
